ElevateBio appoints Steven Falcone as Chief Operating Officer. Steve Falcone brings more than 30 years of operations, quality, and compliance leadership across global biopharmaceutical manufacturing. WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) - ElevateBio, a technology-driven advanced therapy CDMO and gene editing services partner, announced the appointment of Steven Falcone as Chief Operating Officer. Steve brings more than 30 years of experience across technical operations, inspection readiness, quality systems, supply chain, and site management. He has a proven track record of transforming operations and building high-performing leadership teams that bring complex advanced therapies to people and families in need. Steve will be responsible for operations and quality for ElevateBio, ensuring compliant and effective manufacturing and testing at its sites in Waltham, Massachusetts and Pittsburgh, Pennsylvania. His deep industry experience and innovative approach to operations are key to delivering on ElevateBio's mission to reduce the cost of production of advanced therapies. "Steve joins ElevateBio at a pivotal moment as we ready our Waltham site for its first commercial product and expand into our new site in Pittsburgh," said Chris Murphy, Chief Executive Officer of ElevateBio. "We are completely rethinking how advanced therapy plants are operated to help increase access to these transformative medicines. Steve's decades of experience in commercial operations and quality system transformation make him the ideal person to lead this effort." "ElevateBio is shaping the future of advanced therapies through manufacturing and novel technologies, built on a long-standing commitment to quality and innovation that enables our partners to accelerate drug development," said Steve Falcone. "The opportunity now is to bring that same discipline to the economics of manufacturing, applying automation and AI to reduce the cost of goods and produce these therapies reliably at scale. I am honored to join ElevateBio and lead the operations that will help make advanced therapies more accessible to patients who need them." Steve joins ElevateBio from Novo Nordisk, where he served as Vice President of Quality Complaints, Audit and Inspections, and Quality Intelligence, setting strategic direction for the company's global audit, inspection, and complaint programs. His previous roles include Chief Quality Officer for Brammer Bio (acquired by Thermo Fisher) and VP and Senior Director at Thermo Fisher where he transformed their inspection readiness and external engagement programs, as well as supported creation of new business services for advanced therapies including plasmid, mRNA, cell therapy, and regulatory affairs offerings. Prior roles include VP of Quality at Sanofi Genzyme and various quality and operational roles at Amgen, Solstice Neurosciences, and Bayer. Across his career, Steve has led the quality and compliance strategy behind the commercialization and global launch of numerous marketed products, with deep expertise in technology transfer, commercialization, and inspection readiness across multiple jurisdictions. Steve received his B.S. in Chemistry from the University of California, Berkeley. About ElevateBio ElevateBio is a technology-driven advanced therapy contract development and manufacturing organization (CDMO) powering the creation of life-transforming therapies. The Company helps biopharmaceutical partners design, develop, and manufacture therapies from early discovery through commercialization, combining proprietary gene editing technologies and discovery services, cGMP manufacturing capabilities, and industry-leading expertise to accelerate development across a breadth of therapeutic approaches and modalities. Through continuous investment in automation, AI, and next-generation technologies, ElevateBio delivers the quality, speed, and scale partners need to bring advanced therapies to more patients. For more information, visit www.elevate.bio. Steve Falcone. Newly Appointed COO at ElevateBio. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Alabama Business Reporter do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

ElevateBio presented data at the ASGCT 29th Annual Meeting showcasing its expanded gene editing platform and services. The technology-driven advanced therapy CDMO demonstrated capabilities spanning targeted gene insertion using retrotransposon and machine learning-optimised recombinase approaches, plus a new epigenetic editing platform. The company's adenine base editors incorporate AI-designed functional deaminases, enabling targeting of previously inaccessible sites. Its proprietary lipid nanoparticle platform achieved therapeutically relevant in vivo editing across multiple modalities in mice and non-human primates, with favourable tolerability and demonstrated re-dosing capability. ElevateBio's platform spans multiple modalities including nucleases, base editors, reverse transcriptase editors, large gene insertion and epigenetic editors. These capabilities are supported by the company's cGMP manufacturing infrastructure, providing an integrated path from discovery through commercialisation for biopharmaceutical partners.

Sartorius launches next-generation platform to boost efficiency in cell therapy production. EQS-News: SARTORIUS AG / Key word(s): Product Launch Sartorius launches next-generation platform to boost efficiency in cell therapy production (news with additional features) 16.03.2026 / 14:04 CET/CEST The issuer is solely responsible for the content of this announcement. Göttingen, Germany | March 16, 2026 * Eveo Cell Therapy Platform enables automated, multi-parallel intensified production of autologous cell therapies * Compact design can increase output up to fourfold in existing cleanroom space * 90 percent reduction in manufacturing costs possible in CAR-T processes * Successful pilot project with CDMO ElevateBio proves applicability The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to transformative treatments such as CAR-T therapies. With its latest innovation, Sartorius introduces a fundamentally new approach to cell therapy production that strengthens the company's position in the dynamic advanced therapies market. "Cell therapies are redefining medical possibilities. Yet, they remain accessible to only a small share of patients because manufacturing is complex, capacity-constrained and therefore expensive. With our integrated platform, we are tackling these structural bottlenecks head-on," said René Fáber, member of the Executive Board at Sartorius. "By combining raw materials, production equipment, software and QC assays into a scalable system, we enable our customers to expand output, significantly reduce cost per dose and shorten vein-to-vein time for patients." Conventional manufacturing models for autologous cell therapies rely on centralized, purpose-built facilities, that require significant greenfield investment, staff recruitment, training and multi-year build-up phases. Nevertheless, around 60 percent of regulatory disruptions in cell therapy production are caused by manufacturing and process-related issues. The new Eveo platform addresses these challenges by integrating cell selection, activation, gene modification, expansion, wash and concentration and final formulation into a closed system, using a variety of Sartorius solutions from critical raw materials to bioreactors and separation technologies. The system's compact design supports implementation in existing facilities with existing staff, allows for operation in lower-classification environments and supports centralized and decentralized manufacturing models. Sartorius has collaborated with ElevateBio, a leading cell therapy CDMO, amongst other partners, to test out the Eveo platform. In a successful pilot, the system performed in line with design expectations, demonstrating its real-world applicability. Due to its multi-parallel configuration, a single operator can process eight patient batches at once in the same cleanroom space traditionally needed for two batches. Assuming a manufacturing time of around seven days per batch and 50 production weeks per year, Eveo enables production of more than 350 doses per year in a footprint that today yields roughly 100 doses - an almost fourfold increase. Financial modelling confirms that the platform can reduce manufacturing costs by around 90 percent. Quality control also represents a major bottleneck in cell therapy production and release. With Sartorius' capabilities in live cell imaging and high throughput flow cytometry included in the Eveo platform, the technology addresses key analytical challenges and enables accessibility. Sartorius plans to begin taking orders for the Eveo Cell Therapy Platform in September 2026, with first deliveries expected in 2027. ElevateBio is a preferred partner and will be granted access to one of the first Eveo platforms for use with its manufacturing customers. More information about Eveo Cell Therapy Platform A profile of Sartorius Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe. Leona Malorny Head of External Communications +49 551 308 4067 Additional features: 16.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News | Language: | English | | Company: | SARTORIUS AG | | / | Otto-Brenner-Straße 20 | | / | 37079 Göttingen | | / | Germany | | Phone: | +49.(0)551-308.0 | | Fax: | +49.(0)551-308.3289 | | E-mail: | [email protected] | | Internet: | www.sartorius.com | | ISIN: | DE0007165631, DE0007165607 | | WKN: | 716563, 716560 | | Indices: | MDAX, TecDAX | | Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX | | EQS News ID: | 2291956 | | End of News | EQS News Service | 2291956 16.03.2026 CET/CEST